Gault Cheryl sold $332K of RAPP
Gault Cheryl (Chief Operating Officer) sold 10,000 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $33.19 ($33.04–$33.76, $0.33M total) across 2 trades on 2026-09-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size but may be interpreted as a slight negative signal for RAPP's stock.
Market read
Provides fresh insider‑sale data; limited trading relevance due to small size.
What to watch
The 10b5‑1 plan pre‑arranges sales, reducing the informational value of the transaction.
Background
SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.
Ticker impact
COO Gault Cheryl sold 10,000 shares for $331,856 via a 10b5‑1 plan, reducing her stake to 139,914 shares.
likely slight downward pressure as the market prices the insider sell.
A C‑suite insider sold shares worth over $300K; such sales are typically viewed as a bearish signal, especially when executed through a pre‑arranged plan.
Market effects
Minimal; the sale does not affect the broader biotech sector.
None; the filing is company‑specific.
None
Counterpoint
The sale could be routine liquidity for personal needs and not reflect confidence in the company.
Key entities
- companyRapport Therapeutics, Inc.
Biotech firm listed on Nasdaq under ticker RAPP.
- personGault Cheryl
Chief Operating Officer of Rapport Therapeutics.